Session » Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)
- 4:00PM-4:50PM
-
Abstract Number: 0515
A Proof of Concept Study to Assess the Efficacy of Tocilizumab in Combination with Ultra-Short Glucocorticoid Administration to Treat Newly Diagnosed Giant Cell Arteritis – a 24 Week Analysis
- 4:00PM-4:50PM
-
Abstract Number: 0516
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
- 4:00PM-4:50PM
-
Abstract Number: 0514
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
- 4:00PM-4:50PM
-
Abstract Number: 0518
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
- 4:00PM-4:50PM
-
Abstract Number: 0517
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study